Kevin Hrusovsky is a Venture Partner with ARCH focused on new investment opportunities and advising portfolio companies. He has a 30-year career leading life sciences companies, currently serving as Chairman of 908 Devices. He previously held the roles of Executive Chairman, Chairman, and President and CEO at Quanterix (QTRX). Prior to Quanterix, he was CEO of Caliper Life Sciences (CALP – acquired by PKI), and Zymark Corp. (acquired by CALP), as well as, President of Life Sciences at PerkinElmer (PKI). He also held senior roles at FMC Corp. and DuPont. In addition, Kevin created Powering Precision Health foundation, an international non-profit promoting a new era of medicine using biomarker innovation to achieve precision medicine. He is regarded as a pioneering entrepreneur, accelerating adoption and value creation for many game-changing non-invasive early detection technologies for oncology, neuro-degeneration and cardiology, which are transforming drug development and disease prevention.
Kevin is the recipient of several distinguished awards including the 2019 EY Entrepreneur of the Year®, 2017 BBJ Innovation All-Star award for transforming the practices of medicine and health, the 2018 Lifetime Achievement Award for Leadership and the E.G. Bailey Entrepreneurship Award (2013), both from The Ohio State University. Kevin holds an M.B.A. from Ohio University and a B.S. in Mechanical Engineering from The Ohio State University, and received an Honorary Doctorate from Framingham State University for contributions to life sciences.